If you want to know who really controls AbbVie Inc. (NYSE:ABBV), then you'll have to look at the makeup of its share registry. With 73% stake, institutions possess the maximum shares in the company.

In a regulatory filing, AbbVie (ABBV) stated, “Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2024 are expected to include acquired IPR&D and milestones expense ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend growth stocks. Dividend stocks had a challenging year in 2024 as investor interest ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend stocks. Macroeconomic factors have weighed on US stocks in the final days of the ...

"Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with autoimmune diseases." "Nimble Therapeutics is committed to transforming ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

The purchase is just the latest in AbbVie acquisitions this year. AbbVie Inc. said Friday it’s buying Nimble Therapeutics of Madison, Wisconsin, for $200 million. North Chicago-based AbbVie ...

AbbVie presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making ...

AbbVie offers a compelling investment opportunity after a recent price drop, combining dividend income, value, and growth potential driven by a strong drug portfolio and pipeline. Robust growth in ...

(RTTNews) - AbbVie Inc. (ABBV), Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along with certain interim funding and milestone payments.

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...